1. Home
  2. PACB vs IVA Comparison

PACB vs IVA Comparison

Compare PACB & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PACB
  • IVA
  • Stock Information
  • Founded
  • PACB 2000
  • IVA 2011
  • Country
  • PACB United States
  • IVA France
  • Employees
  • PACB N/A
  • IVA N/A
  • Industry
  • PACB Biotechnology: Laboratory Analytical Instruments
  • IVA Biotechnology: Pharmaceutical Preparations
  • Sector
  • PACB Industrials
  • IVA Health Care
  • Exchange
  • PACB Nasdaq
  • IVA Nasdaq
  • Market Cap
  • PACB 364.2M
  • IVA 359.6M
  • IPO Year
  • PACB 2010
  • IVA 2020
  • Fundamental
  • Price
  • PACB $1.37
  • IVA $3.39
  • Analyst Decision
  • PACB Buy
  • IVA Strong Buy
  • Analyst Count
  • PACB 9
  • IVA 4
  • Target Price
  • PACB $2.06
  • IVA $10.50
  • AVG Volume (30 Days)
  • PACB 9.3M
  • IVA 15.5K
  • Earning Date
  • PACB 08-06-2025
  • IVA 03-26-2025
  • Dividend Yield
  • PACB N/A
  • IVA N/A
  • EPS Growth
  • PACB N/A
  • IVA N/A
  • EPS
  • PACB N/A
  • IVA N/A
  • Revenue
  • PACB $152,357,000.00
  • IVA $14,591,573.00
  • Revenue This Year
  • PACB $3.33
  • IVA $15.38
  • Revenue Next Year
  • PACB $17.88
  • IVA $24.22
  • P/E Ratio
  • PACB N/A
  • IVA N/A
  • Revenue Growth
  • PACB N/A
  • IVA N/A
  • 52 Week Low
  • PACB $0.85
  • IVA $1.53
  • 52 Week High
  • PACB $2.72
  • IVA $4.05
  • Technical
  • Relative Strength Index (RSI)
  • PACB 52.51
  • IVA 46.85
  • Support Level
  • PACB $1.36
  • IVA $3.21
  • Resistance Level
  • PACB $1.62
  • IVA $3.49
  • Average True Range (ATR)
  • PACB 0.11
  • IVA 0.20
  • MACD
  • PACB -0.01
  • IVA 0.01
  • Stochastic Oscillator
  • PACB 41.98
  • IVA 32.35

About PACB Pacific Biosciences of California Inc.

Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.

About IVA Inventiva S.A. American Depository Shares

Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.

Share on Social Networks: